AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05370170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure and nutritional advices
Description: Teaching using booklets and application of acupressure
Study NCT05259917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to KVD900 Tablet
Study NCT05259917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900 600 mg
Description: KVD900 Tablet 600 mg (2 x 300 mg)
Study NCT05259917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900 300 mg
Description: KVD900 Tablet 300 mg (1 x 300 mg)
Study NCT05429840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1980
Description: single dose
Study NCT05429840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study NCT05622006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary breaks
Description: Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
Study NCT03252626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil
Description: Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.~2ml Alprostadil injection added into 10ml 0.9% saline.
Study NCT03252626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2ml normal saline injection added into 10ml 0.9% saline.
Study NCT04682301 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral Intervention
Description: Receive SDM intervention
Study NCT04682301 — intervention group
Intervention type: OTHER
Intervention: Discussion (focus group)
Description: Attend focus group
Study NCT04682301 — intervention group
Intervention type: OTHER
Intervention: Discussion (feedback on SDM)
Description: Provide feedback on SDM
Study NCT04682301 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Attend a telephone interview
Study NCT04682301 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05046600 — intervention group
Intervention type: DEVICE
Intervention: Products listed in cohort description
Description: Depending on approved indication per product
Study NCT06477978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hand grip function testing
Description: The use of Bio-impedance to measure the skeletal muscle mass
Study NCT05247762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
Study NCT05247762 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
Study NCT06429241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: single dose injection (120 million cells)
Study NCT04929015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - blood and tissue sample collection
Description: The original tissue sample from each patient will be obtained at time of surgery or prior to surgery. Plasma for ctDNA will be obtained at baseline, pre-surgery, post-surgery and every 3 months up 2 years
Study NCT04929015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical record reviewed
Study NCT06132438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP-CMV vaccine
Description: The PEP-CMV vaccine is a long synthetic peptide (PEP) made up of 26 amino acids that is derived from the human cytomegalovirus (CMV) matrix protein pp65 and has both MHC class I and II epitopes. A vaccine platform that initially consists of TMZ-induced lymphopenia and Td pre-conditioning will be used, with serial vaccinations of up to 12 times (maximum 20) being applied. To ensure the effectiveness of the future Td pre-conditioning, which is given right before the initial PEP-CMV vaccine, a Td booster is required at enrollment.
Study NCT06488989 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: left bundle branch area pacing
Description: Cardiac resynchronization therapy obtained by conduction system pacing
Study NCT06491498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Supraclavicular Brachial Plexus Blockade
Description: Hemidiaphragmatic Paralysis Following Ultrasound-Guided Supraclavicular Brachial Plexus Blockade in patients undergoing upper limb surgery
Study NCT06270134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate
Description: Bicarbonate is added to hemodialysis fluids to correct the metabolic acidosis that arises from kidney failure. Some dialysis units in Canada add bicarbonate to a level of 32 mmol/L, while other units add bicarbonate to a level of 38 mmol/L. It is unknown whether one level is better for people's health.
Study NCT04903301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contoura Vision LASIK
Description: Topography-Guided LASIK using Phorcides Analytic Software
Study NCT04835350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreas4ALL - meal announcement or full closed loop
Description: Patient using AID Pancreas4ALL in mode meal announcment or full closed loop.
Study NCT06218862 — intervention group
Intervention type: DRUG
Intervention: Sivelestat sodium
Description: Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for at least 72 hours and a maximum duration of 14 days.
Study NCT06218862 — intervention group
Intervention type: DRUG
Intervention: Control
Description: Not use Sivelestat sodium
Study NCT06356675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg iv D1 Q3W
Study NCT06356675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg D1-12 Q3W
Study NCT05152719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Performance
Description: Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
Study NCT05152719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Performance
Description: Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
Study NCT05945641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Load Resistance training
Description: Performing single leg knee extension exercise with using equivalent to \~30%1-RM to failure,
Study NCT05945641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint/High Intensity Interval Training
Description: Performing repeated submaximal/maximal 30second-60 seconds (1-3 minute rest between) aerobic intervals on a Kicking ergometer (modified bike that allows cycling to be performed with one leg using a kicking motion).
Study NCT05965609 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBTI
Description: Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
Study NCT05965609 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MRTI
Description: Intervention includes education about sleep and behavioral and relaxation strategies to improve sleep
Study NCT04997343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurophysiological assessment
Description: EMG will be recorded from the Abductor pollicis brevis muscle (APB) with surface electrodes. EEG will be recorded with a 32-channel elastic cap via a TMS compatible system. TMS will be performed using a Magstim 200 stimulator with a 90 mm figure-of-eight coil localized on motor and non-motor areas using a neuronavigation system together with an optical tracking system. Coordinates for neuronavigation will be calculated in the MNI space and fit of each participant's anatomical MRI. Three minutes of continuous-EEG will be recorded with subjects at rest. Single-pulse neuronavigated TMS (sp-TMS) will be delivered at rest below the resting motor threshold intensity (RMT) over the APB hotspot on M1 during concurrent EEG recording. In a final block, the subject will maintain a voluntary muscle contraction (50% of the maximal voluntary contraction) of the left APB, and sp-TMS will be delivered at 130% RMT over the ipsilateral APB hotspot in order to record the lpSP.
Study NCT04997343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological assessment
Description: EMG will be recorded from the Abductor pollicis brevis muscle (APB) with surface electrodes. EEG will be recorded with a 32-channel elastic cap via a TMS compatible system. TMS will be performed using a Magstim 200 stimulator with a 90 mm figure-of-eight coil localized on motor and non-motor areas using a neuronavigation system together with an optical tracking system. Coordinates for neuronavigation will be calculated in the MNI space and fit of each participant's anatomical MRI. Three minutes of continuous-EEG will be recorded with subjects at rest. Single-pulse neuronavigated TMS (sp-TMS) will be delivered at rest below the resting motor threshold intensity (RMT) over the APB hotspot on M1 during concurrent EEG recording. In a final block, the subject will maintain a voluntary muscle contraction (50% of the maximal voluntary contraction) of the left APB, and sp-TMS will be delivered at 130% RMT over the ipsilateral APB hotspot in order to record the lpSP.
Study NCT04997343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical assessment
Description: Clinical evaluation, performed at each time point, will include:~* The assessment of clinical disability using EDSS score~* The multiple sclerosis functional composite (MSFC), a three-part quantitative objective measure of neurologic function, measuring lower limbs (timed 25-foot walk \[T25FW\]), upper limbs (nine-hole peg test \[9HPT\]) and cognitive (three-second paced auditory serial addition test \[PASAT3\]) function.~In order to reduce inter-rater variability, the same physician/technician with adequate training will administer all three tests. The patient should feel comfortable with the situation. Examiner should explain the instructions in a professional but friendly way and let the patient ask any questions before starting the tests. Examiner should write down the test results, as well as any situation that disturbs the performance of patient. Examiner should not provide direct feedback to the patient about his/her performance
Study NCT05110352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: A polysmnography is planned for every patients in order to evaluate the Apnea-Hypopnea Index (AHI).
Study NCT05110352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharyngeal ph-metry Restech
Description: Pharyngeal ph-metry Restech over 24 hours (night and day)
Study NCT05110352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptest
Description: Saliva sample to look for an association between pharyngolaryngeal reflux and obstructive sleep apnea syndrome
Study NCT05110352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire RSS-12
Description: Questionnaire with 12 items about quality of life. Score between 0 and 5.
Study NCT05110352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflux Sign Assessment
Description: RSA score about anatomy and morphology of the mouth
Study NCT05413603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic focus Shock wave lithotripsy
Description: successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone
Study NCT05413603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopic focus Shock wave lithotripsy
Description: successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone
Study NCT04961359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT04961359 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
Study NCT05298241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-grip Strength Game
Description: Interactive Handgrip Strength Game for ICU patients receiving the game and to assess the impact on psychological.
Study NCT06380283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Use of a virtual reality headset during pediatric dental care
Study NCT05644496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release
Description: Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
Study NCT04913922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: s.c. 75 mg/m2 BSA for 7 days
Study NCT04913922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg i.v.
Study NCT04913922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: 80-160mg i.v.
Study NCT06157476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretch-shortening exercise
Description: The SSC-Ex program was conducted for 35 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
Study NCT06157476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise program
Description: The standard exercise program lasted for 35 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, manual guidance, and functional training.
Study NCT06031285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Perioperative Sinitilimab, bevacizumab biosimilar and TACE-HAIC
Study NCT05414188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation runs for 60 minutes per session. The pulmonary rehabilitation program is based on a comprehensive approach, not simply providing regular exercise. And it includes patient education, active encouragement, and psychological support by investigators. Exercise is performed more than twice a week. Each session is performed for 60 minutes and includes breathing exercises, low to medium-intensity aerobic exercises, and muscle exercises under the guidance of a investigator. After radiation therapy is completed, investigators will recommend that patients perform pulmonary rehabilitation at home more than twice a week and for 60 minutes or more. The patients will record whether and when exercise is performed every day in the diary for pulmonary rehabilitation.
Study NCT05387642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo
Description: Single dose with a washout period between doses
Study NCT05387642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PRAX-114 or 20 mg PRAX-114
Description: Once daily oral treatment for 28 days
Study NCT05026554 — intervention group
Intervention type: GENETIC
Intervention: Tape stripping
Description: Optional genetic analysis for chronic hand eczema
Study NCT05407883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School traffic warden programme
Description: Trained school traffic wardens placed at school crossing points to help children cross
Study NCT05441189 — intervention group
Intervention type: PROCEDURE
Intervention: Resection
Description: radical R0 resection of pancreatic adenocarcinoma
Study NCT05295407 — intervention group
Intervention type: GENETIC
Intervention: Genetic Assessment
Description: The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
Study NCT04469127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium-177-DOTAGA-IAC
Description: Study participants be administered therapeutic doses of Lutetium-177-DOTAGA-IAC up to three treatments spaced 4 weeks apart.
Study NCT04765904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 1)Dry with cotton to affected tooth surfaces 2) Apply the SDF material 3)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
Study NCT04765904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up
Study NCT04869007 — intervention group
Intervention type: DEVICE
Intervention: hysterosonography
Description: Isthmocele mesured by hysterosonography before ART procedure
Study NCT05086276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FX-322
Description: Active Comparator
Study NCT05086276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05280990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mHBS
Description: Preoperative FLRF assessment using 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS).
Study NCT05280990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT/MRI volumetry
Description: Preoperative FLRF assessment using CT/MRI volumetry
Study NCT04832737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADDapt Ability Framework
Description: 12 week individual therapeutic coaching intervention
Study NCT05252338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVSQIV
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study NCT06391411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg)
Description: In this three-arm randomized, controlled trial, with one arm represented by healthy subjects, eligible participants were randomly divided into two groups. Fifteen patients were randomly allocated to the intervention group and received, for 6 months, intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen and daily supplementation with a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg). The other fifteen patients was assigned to the control group and only received the intravitreal anti-VEGF treatment at a fixed regimen for 6 months
Study NCT06391411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-VEGF treatment
Description: Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months
Study NCT06391411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-VEGF treatment
Description: Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months
Study NCT05187221 — intervention group
Intervention type: BEHAVIORAL
Intervention: CVS Group
Description: CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
Study NCT06294561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole+TGRX-326
Description: healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Itraconazole 200 mg with TGRX-326 60 mg orally on day 11
Study NCT06294561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz+TGRX-326
Description: healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Efavirenz 600 mg with TGRX-326 60 mg orally on day 20